Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribonucleic acid K10
- Development stage
- Unknown
- Lead developer
- Labo'Life
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
Ribonucleic acid K10 is a micro-immunotherapy component developed by Labo'Life Belgium, primarily utilized in the treatment of Epstein-Barr virus (EBV) infections, including infectious mononucleosis and chronic fatigue syndrome associated with EBV. It consists of ribonucleic acid (RNA) prepared at a 10K (Korsakovian) dilution. As a part of the micro-immunotherapy framework, it is typically included in complex formulations like 2LEBV, which combine various cytokines (such as IL-1, IL-2, and IFN-gamma) and specific nucleic acids (SNA) at sequential homeopathic dilutions. The therapeutic intent is to modulate the host's immune response and potentially interfere with viral replication through sequence-specific interactions, aiming to restore immune homeostasis. The drug is administered sublingually in the form of globules to facilitate absorption through the oral mucosa.
- Brand names
- 2LEBV
- Other names
- RNA 10KRNA10KRNA-10KRibonucleic acid 10KAcide ribonucléique 10K
Beyond the preview
Go deeper on ribonucleic acid K10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribonucleic acid K10.